ReviewJournal of clinical virology : the official publication of the Pan American Society for Clinical Virology2015
Ebola and Marburg haemorrhagic fever.
Review in Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
84 citing papers in PubMed, 148 citations in OpenAlex.
- Pan-filovirus activity of an IGF2-fused monoclonal antibody: Impairment by IGF1R cross-engagement and rescue via IGF2 Y27L mutation.Virus research · 2026Article
- Emerging Viral Zoonoses: Epidemiology, Vaccination Strategies, and Implications for Global Public Health.Vaccines · 2026Review
- Biosecurity and Diagnosis of Viral Hemorrhagic Fevers: Strategic Considerations for Military Medicine.Diagnostics (Basel, Switzerland) · 2026Review
- Differences in cynomolgus macaque populations used for infectious disease research.Animal models and experimental medicine · 2026Review
- Review
- A surrogate BSL2-compliant infection model recapitulating key aspects of human Marburg virus disease.Emerging microbes & infections · 2025Article
- Thermostable bivalent & trivalent filovirus vaccines from insect cells: potency demonstrated after 3 months and 2 years.Vaccine · 2025Article
- Behavioral risk assessment of exposure to wild and domestic animals in response to a Marburg virus disease outbreak, Ghana 2022.One health (Amsterdam, Netherlands) · 2025Article
- Immunogenicity, Pathogenesis, and Host's Immuno-Responses to Marburg Virus Infection.Pathogens (Basel, Switzerland) · 2025Review
- Cellular Phenotyping of Peripheral Blood Mononuclear Cells from Marburg Virus-Infected Animals.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Studying bats using a One Health lens: bridging the gap between bat virology and disease ecology.Journal of virology · 2024Review
- Organotypic brain slices as a model to study the neurotropism of the highly pathogenic Nipah and Ebola viruses.The Journal of general virology · 2024Article
- Development of a Měnglà virus minigenome and comparison of its polymerase complexes with those of other filoviruses.Virologica Sinica · 2024Article
- Design and characterization of protective pan-ebolavirus and pan-filovirus bispecific antibodies.PLoS pathogens · 2024Article
- Ebola virus VP35 perturbs type I interferon signaling to facilitate viral replication.Virologica Sinica · 2023Article
- Emerging Infectious Diseases Are Virulent Viruses-Are We Prepared? An Overview.Microorganisms · 2023Review
- Marburg and Ebola Virus Infections Elicit a Complex, Muted Inflammatory State in Bats.Viruses · 2023Article
- Pathogenicity and virulence of Marburg virus.Virulence · 2022Review
- Protective CD8+ T Cell Response Induced by Modified Vaccinia Virus Ankara Delivering Ebola Virus Nucleoprotein.Vaccines · 2022Article
- Macrophage infection, activation, and histopathological findings in ebolavirus infection.Frontiers in cellular and infection microbiology · 2022Review
24 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 4 countries.
Funding
Abstract
Ebolaviruses and Marburgviruses (family Filoviridae) are among the most virulent pathogens for humans and great apes causing severe haemorrhagic fever and death within a matter of days. This group of viruses is characterized by a linear, non-segmented, single-stranded RNA genome of negative polarity. The overall burden of filovirus infections is minimal and negligible compared to the devastation caused by malnutrition and other infectious diseases prevalent in Africa such as malaria, dengue or tuberculosis. In this paper, we review the knowledge gained on the eco/epidemiology, the pathogenesis and the disease control measures for Marburg and Ebola viruses developed over the last 15 years. The overall progress is promising given the little attention that these pathogen have achieved in the past; however, more is to come over the next decade given the more recent interest in these pathogens as potential public and animal health concerns. Licensing of therapeutic and prophylactic options may be achievable over the next 5-10 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.